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ORIGINAL ARTICLE
Meningeal carcinomatosis (MC) is defined as
diffuse or multifocal metastases from solid tumors
to the leptomeninges, with or without associated
brain parenchymal lesions.1,2 Lung cancer and
breast cancer are the most frequently encountered
solid tumors associated with MC.3–5 MC is diag-
nosed with increasing frequency, probably due to
the increasing incidence of this form of metastasis
in the longer survival of patients with systemic
chemotherapy and also because diagnosis has
been more aggressively pursued.6,7 Although the
increasing availability of magnetic resonance im-
aging may contribute to the rising rate of diagnosis
of MC,8,9 a definitive diagnosis still depends on
the presence of malignant cells in the cerebro-
spinal fluid (CSF).1,10,11 Prognosis is poor if the
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diagnosis is delayed and there is no aggressive
treatment after the diagnosis.1,3,4,12,13 The standard
treatments, including whole brain irradiation,
intrathecal chemotherapy and other palliative
modalities, have proven to be more effective in
MC from breast cancer than in MC from lung
cancer.3,5,14 The survival not only depends on
prompt diagnosis and treatment of MC, but also
the general condition of the patient.14–16
Previous reports of MC mainly discussed the
overall features of MC from different solid tumors,
including breast cancer, lung cancer, melanoma,
etc.1–3,14–16 However, the clinical features of MC
exclusively in lung cancer patients have not been
well identified and characterized. The purpose 
of this report is to present the clinical features,
laboratory findings, treatment and survival of 
34 patients with MC from lung cancer in the past
11 years at a medical center.
Methods
We reviewed all cases of malignant CSF cytology
at the National Taiwan University Hospital be-
tween January 1992 and December 2002. Only
cases of histologically or cytologically proven
(i.e. CSF cytology from lumbar puncture, ven-
triculoperitoneal [VP] shunt, Ommaya reservoir,
or excision of the brain tumor) MC caused by
lung cancer were selected. The total number of
lung cancer patients during the same period was
collected from the Cancer Registry, Office of
Medical Records, at the National Taiwan University
Hospital.
Clinical data collected included gender, age,
smoking status, neurological symptoms and signs
at diagnosis, duration of neurologic symptoms,
and interval between diagnosis of primary lung
cancer and MC.
CSF data collected included open pressure,
differential cell count, biochemistry profiles and
cytology. The parameters of CSF data were obtained
from the initial positive CSF cytology sample.
However, not all parameters of CSF data were
available for every patient.
The clinical stage at the time of diagnosis of MC
was determined using the TNM staging system.17
Therapeutic regimens for primary lung cancer,
including surgery, radiotherapy, systemic chemo-
therapy and supportive care were recorded. Treat-
ment of MC was individualized for each patient
including whole brain irradiation (3000 cGy in
15 fractions for the standard treatment course),
intrathecal injection of methotrexate (IT-MTX,
7 mg/m2 body surface area through an Ommaya
reservoir or lumbar puncture once a week), VP
shunt implantation, supportive care or combina-
tions of these treatments. The response of MC to
treatment was defined as improvement if there
was clear symptomatic relief of either some or all
of the neurologic symptoms or signs that were sus-
tained throughout the first 4 weeks of treatment.14
No improvement was defined when neurologic
symptoms or signs persisted or deteriorated during
the first 4 weeks of treatment.
Statistical analysis
The duration of survival was measured from the
date of the diagnosis of MC to death. The survival
data was followed up and updated to the present
time. Survival curves were plotted using the Kaplan-
Meier method and examined by the log-rank
test. The statistical significance level was set at
p < 0.05 in a two-tailed test. Statistical analysis




We identified 34 patients, 18 males and 16 
females, with a diagnosis of lung cancer and MC
from the period of January 1992 to December
2002. During the same period, 4705 patients had
a confirmed diagnosis of lung cancer. The inci-
dence of MC from lung cancer was 0.38% in
1992 and increased to 1.86% in 2002. MC oc-
curred in approximately 0.7% of the lung cancer
patients. The median age was 60 years, with a
range of 42 to 78 years. The characteristics of the
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patients with a diagnosis of MC are listed in
Table 1.
CNS manifestations and CSF examinations
Thirteen patients (38%) had either concurrent
radiographic evidence or a history of brain metas-
tases. Three patients had concurrent diagnosis of
brain metastases and MC at the same time. Ten
patients had a history of brain metastases and nine
of them had received whole brain irradiation be-
fore the diagnosis of MC. The most common
neurologic symptoms before the diagnosis of brain
metastases and MC were the same, including dis-
turbance of consciousness, followed by headache
and vomiting. Twenty-one patients without evi-
dence of brain metastases reported headache as
the most frequent neurologic symptoms, followed
by unstable gait and disturbance of consciousness.
MC produced the first symptoms of the primary
tumor in nine patients (26%) and led to the di-
agnosis of lung cancer. The median duration of
neurologic symptoms at presentation was 42 days,
with a range of 8–265 days. The presenting neu-
rologic symptoms and signs are summarized in
Table 2. The signs and symptoms were clinically
localized to two levels of the neuraxis in 17 patients
(50%) and involved all three levels in only five
patients (15%).
CSF cytology revealed adenocarcinoma in 32
patients, and squamous cell carcinoma and small
cell carcinoma in one each. The opening pressure
was elevated above 160 mmH2O in 18 of 23 pa-
tients (74%) in whom it was recorded. Overall,
35% of 23 patients had a leukocyte count above
5/μL. There were 44% of 25 patients with glu-
cose concentrations below 45 mg/dL. The protein
concentrations were elevated above 0.05 g/dL in
69% of 26 patients.
Treatment response and survival
Because of neurologic instability, systemic disease
or infection, 10 patients received supportive care,
seven patients received VP shunt implantation and
one received three doses of 12 mg IT-MTX. Sixteen
patients received whole brain irradiation includ-
ing three with a VP shunt, three with IT-MTX and
two with systemic chemotherapy. Only 10 patients
(62.5%) completed more than 12 fractions of
whole brain irradiation and only one patient
(33.3%) received more than three doses of IT-MTX.
All 16 patients who received whole brain irradia-
tion tolerated it well and no infection occurred
in any of the 10 patients who underwent VP shunt
implantation. One patient suffered a seizure after
the first dose of IT-MTX. No other complication
Table 1. Characteristics of 34 patients with




Age at diagnosis of MC, yr 60 (42–78)
Smoking status 18/16
(smoker/nonsmoker)




Lung to lung 3
Adrenal gland 1
Duration of neurologic symptoms 42 (8–265)
before diagnosis of MC, d
Interval between diagnosis of 223 (−14–3995)
lung cancer and MC, d
*Data presented as n or median (range).
Table 2. Symptoms and signs at diagnosis of




Consciousness disturbance 15 (44)
Unstable gait 15 (44)




Cranial nerve involvement 15 (44)
Mental change 10 (29)
Cerebellar signs 9 (26)
Lower motor neuron deficits 8 (24)
Kernig’s sign 7 (21)
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occurred with IT-MTX treatment. Improvement
was noted in seven patients during the first 4 weeks
of treatment. Among them, six received whole
brain irradiation (including two combined VP
shunt implantation and two combined IT-MTX)
and one received VP shunt implantation only. Two
patients who survived the first 8 weeks after diag-
nosis and whole brain irradiation for MC received
systemic chemotherapy (standard cisplatin plus
gemcitabine regimens) for stage IV lung cancer.
They were followed-up for more than 1 year. One
of the patients died because of septic shock 76
weeks after diagnosis of MC and the other died
because of neurologic complications 82 weeks
after diagnosis of MC.
All patients died during the follow-up period.
The overall median survival was 5.1 weeks. Survival
curves for all patients, based on treatment with
whole brain irradiation (including combination
therapy) and treatment without whole brain irra-
diation, are presented in the Figure. Median sur-
vival times for whole brain irradiation and other
treatments were 5.6 weeks and 2.9 week, respec-
tively. There was no significant difference in survival
curves between those with whole brain irradiation
and without whole brain irradiation (p = 0.202,
log-rank test).
Discussion
Leptomeningeal metastasis, once thought to be 
a rare neurologic complication of solid tumors,
has shown an increase in frequency over the past
decades.15,18 We also observed an increased inci-
dence of MC in our lung cancer patients from
1992 to 2002. This could be matched to the 
increasing number of lung cancer patients, the
increasing incidence of leptomeningeal metasta-
sis in lung cancer patients with longer survival
after systemic chemotherapy, and the increasing
awareness of this disease. However, previous 
reports indicated leptomeningeal metastasis oc-
curred in approximately 5% of patients with
breast cancer and non-small cell lung can-
cer.15,16,19,20 The incidence was higher in patients
with small cell lung cancer (9–25%) and mela-
noma (23%).6,7,20 Recently, Sudo et al reported
that MC occurred in approximately 2.4% of lung
cancer patients in Japan during 2001–2005.21
Our study revealed a considerably lower occur-
rence (approximately 0.7%) of MC from lung
cancer in Taiwan. This could be due to underesti-
mation of case numbers of MC from cytologic
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Figure. Survival based on treatment with and without whole brain irradiation (p = 0.202).
The clinical presentation before the diagnosis of
MC in our study was similar to previous reports
in patients with a solid tumor with MC.3,16,19
There was no difference in the symptoms and signs
of those patients with MC and those with brain
metastasis in our study. Therefore, headache and
disturbance of consciousness should raise the
suspicion not only of brain metastasis but also
of MC in lung cancer patients. The interval be-
tween the diagnosis of the primary tumor and
MC is quite different in patients with breast cancer
and lung cancer. Sudo et al reported that the time
from the date of diagnosis of lung cancer to the
date of diagnosis of MC ranged from −2 days to 8
years (median, 407 days).21 Boogerd et al reported
that the diagnostic interval between breast cancer
and MC ranged from 3 months to 19 years (me-
dian, 38 months).16 The duration of the diagnostic
interval in our study is very similar to other lung
cancer patients but is quite different from breast
cancer patients. This could be due to longer sur-
vival time in breast cancer patients than in lung
cancer patients. In our study, adenocarcinoma
comprised most of the CSF cytology findings.
This is unique from previous reports.3,5,14 This
may be due to the relatively small number of cases
of small cell lung cancer in Chinese compared
with Caucasians.22
Radiation therapy directed to the sites of major
clinical involvement and intrathecal chemotherapy
were thought of as treatment protocols for MC
from a solid tumor.3,14,23 However, such therapies
were less effective in treatment of MC from lung
cancer.5,19 Because the clinical presentations be-
fore the diagnosis of MC and brain metastasis
were the same, lumbar puncture was essential to
confirm the diagnosis of MC because whole brain
irradiation could not prolong survival in patients
with MC from lung cancer. Four of six patients
with improved neurologic conditions also had
other treatment modalities including VP shunt
implantation and IT-MTX. VP shunt implantation
was thought to be a palliative treatment in com-
bined modality therapy for MC,24 especially for
those who had received whole brain irradiation
for brain metastasis before the diagnosis of MC.
Intrathecal chemotherapy with gemcitabine might
prove to be more suitable for MC induced by
lung cancer as in case reports and such therapy is
worth further study.25
The most documented article regarding com-
bined modality therapy for MC due to non-small
cell lung cancer is that of Chamberlain and
Kormanik, a study of 32 patients with a median
survival of 5 months (range, 1–12 months).19 The
study was prospective and patients with poor
performance status were excluded. Similar to pre-
vious studies, Chamberlain and Kormanik used
intrathecal chemotherapy as a standard treatment
for all 32 patients with MC. In addition, 16 patients
received radiation therapy and 12 had concurrent
brain metastasis.19 Perhaps the study design could
account for the longer survival in their study. The
median survival rate in our study was considerably
shorter than another retrospective study of 37
Japanese patients with lung cancer and MC (5.1
weeks and 15.1 weeks, respectively). This could
be due to the fact that gefitinib was most often
used for therapy after the onset of MC in the
study.21 Both our data and that of Sudo et al indi-
cated that lung cancer patients with MC could
survive for longer than 1 year. It is possible, if pa-
tients survive the initial neurologic complications
from MC, that they still have a chance to battle
lung cancer with chemotherapy or gefitinib/
erlotinib target therapy and have longer survival.
Therefore, whole brain irradiation plus another
treatment modality such as intrathecal chemother-
apy or VP shunt implantation could be essential
to treat MC from lung cancer.
There were several limitations in this study.
First, it was a retrospective study of therapeutic
outcome and selection bias remains a potential
source of error. Second, the number of patients
was small and mainly limited to lung adenocarci-
noma with MC. Third, the most advanced therapies
were not included in our study such as intrathecal
gemcitabine chemotherapy and gefitinib/erlotinib
target therapy for lung cancer with MC. There-
fore, a prospective study would be necessary to
establish the effectiveness of combined modality
therapy.
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In conclusion, the prognosis of MC from lung
cancer is poor. Although MC is a rare complication
of lung cancer in Taiwan, the clinical presentation
of MC and brain metastasis are the same and MC
could be easily missed if there is no further inves-
tigation to confirm the diagnosis of MC. Because
whole brain irradiation could not prolong sur-
vival in patients with MC from lung cancer, com-
bined modality therapy including whole brain
irradiation, intrathecal chemotherapy and VP shunt
implantation could be essential to treat patients
with MC from lung cancer. Those who survive
the neurologic complications from MC could have
more chance of treatment for lung cancer with
chemotherapy or target therapy.
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